** GoodRX shares rise 1.3% to $4.65 after the bell
** Co appoints Wendy Barnes as president and chief executive officer effective January 1, 2025
** Barnes previously held the position of CEO at RxBenefits
** As CEO, Wendy will focus on bringing all brand affordability programs onto the GoodRx platform, expanding GoodRx's product experience with healthcare professionals and enriching partnerships with retail pharmacies, insurers and pharmaceutical manufacturers - GDRX
** Barnes replaces Scott Wagner, who was the interim CEO at the company, appointed in April 2023
** 9 of 18 brokerages rate the stock "buy" or higher, 8 "hold" and 1 "sell"; their median PT is $7
** YTD, GDRX down 31.4%
(Reporting by Abhinav Parmar in Bengaluru)
((Abhinav.parmar@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。